Developer docs
API playgroundTry for free, no card

Search company profiles

Northern Leaf

Full company profile

uuid000317l

Namestring
Northern Leaf
Legal namestring
Northern Leaf
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Northern Leaf is a Jersey-based medical cannabis cultivator operating under a bulk EU-GMP licence, producing pharmaceutical-grade cannabis for export to UK and European pharmaceutical supply chains. Founded in the wake of Jersey's 2017 regulatory changes permitting medicinal cannabis cultivation, the company utilizes repurposed greenhouses on the island as its primary production infrastructure and is positioned as a major employer within Jersey's nascent biopharmaceutical sector, which collectively employs approximately 70 people.

Short descriptiontext

Northern Leaf is a Jersey-based, EU-GMP-certified medical cannabis cultivator that produces pharmaceutical-grade cannabis for export to UK and European pharmaceutical distributors. The company operates on a pre-sold B2B model, exporting approximately 6 tons annually with planned expansion to 9 tons.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSt. Helier
HQ citystring
St. Helier
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical cannabis cultivation, pharmaceutical cannabis production, EU-GMP certified cannabis, bulk cannabis supply, medical marijuana manufacturing
Industry1 code
PRIMARYCRAOAIAF
Cannabis Wholesale Distribution (Flower, Extracts, Edibles)
Consumer Products & Retail/Wholesale, Distribution & Category Management/Alcohol, Tobacco & Cannabis Wholesale Distribution
NAICS code3 codes
  • Medicinal and Botanical Manufacturing325411
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Medical Cannabis Cultivation
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Cannabis Product Sales
TypeHardware Sales
Description

Northern Leaf generates revenue through the production and sale of medical cannabis to pharmaceutical supply chains. The company exports cannabis products to UK and European pharmaceutical markets. All production over the past five months has been sold, and future harvests are pre-sold into target markets, indicating a strong demand-driven revenue model with contracted sales.

mmjdaily.com
Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Operations, Personnel, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Northern Leaf cultivates and produces pharmaceutical-grade medical cannabis in Jersey under a bulk EU-GMP licence. The company exports approximately 6 tons of medical cannabis in 2025 with plans to increase to 9 tons in 2026, supplying UK and European pharmaceutical companies and distributors. All recent production has been pre-sold into target markets, indicating contracted B2B supply relationships.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Northern Leaf operates as a single-product medical cannabis company focused on cultivation and production of pharmaceutical-grade cannabis. The company holds a bulk EU-GMP licence enabling it to supply the UK and European pharmaceutical markets. All production is pre-sold into target markets, with the company exporting approximately six tons annually and planning to increase to nine tons in subsequent years. The core product is the medical cannabis production output itself, which serves the regulated pharmaceutical supply chain.

Product and service1 record
1Medical Cannabis Production
CategoryMedical Cannabis Cultivation
Description

Cultivation and production of pharmaceutical-grade medical cannabis under a bulk EU-GMP licence for export to UK and European pharmaceutical supply chains. Operating from repurposed greenhouses in Jersey, with production scaled to approximately 6 tons in 2025 and planned 9 tons in 2026.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
1Tilray Brands
TypeBroad incumbent
Description

Large global cannabis company with significant medical cannabis operations in Europe, including Portugal-based cultivation and EU-GMP certified production. Comparable to Northern Leaf as a competing supplier of EU-GMP certified medical cannabis to European pharmaceutical supply chains, but at vastly greater scale and broader product range.

TypeBroad incumbent
Description

Major Canadian-listed cannabis producer with EU-GMP facilities in Europe supplying medical cannabis to UK and German markets. Comparable as a competing EU-GMP-certified bulk medical cannabis exporter, though Aurora operates at significantly larger scale with a broader product portfolio.

TypeBroad incumbent
Description

Global cannabis producer with medical cannabis operations across Europe, including Spectrum Therapeutics. Comparable to Northern Leaf in targeting the UK and European medical cannabis supply chains with EU-GMP certified product, but with much broader geographic reach and product range.

TypeBroad incumbent
Description

Operates one of the largest EU-GMP certified medical cannabis production facilities in Europe (Portugal) and supplies pharmaceutical distributors across the UK and EU. Direct comparable to Northern Leaf in product category (EU-GMP bulk medical cannabis) and customer base, but at much greater scale.

TypeDirect peer
Description

Canadian cannabis producer that has invested in EU-GMP certified production (Germany) to supply the European medical cannabis market. Comparable to Northern Leaf in business model (EU-GMP certified bulk medical cannabis exporter to European pharma supply chains).

TypeDirect peer
Description

Australian medical cannabis producer with EU-GMP certified Danish operations supplying European pharmaceutical markets. Highly comparable to Northern Leaf as a smaller-scale EU-GMP certified medical cannabis exporter focused on European B2B pharmaceutical supply chains.

TypeDirect peer
Description

German medical cannabis producer holding a domestic cultivation licence and supplying the German and broader European pharmaceutical market. Comparable to Northern Leaf as a regional EU-GMP certified medical cannabis cultivator serving European pharmaceutical supply chains.

TypeDirect peer
Description

Dutch medical cannabis producer with decades of experience supplying pharmaceutical-grade cannabis to European markets under strict regulatory frameworks. Comparable to Northern Leaf in product category (EU-GMP-equivalent pharmaceutical grade medical cannabis) and customer base, though Bedrocan is a long-established incumbent.

TypeDirect peer
Description

Danish medical cannabis company supplying pharmaceutical-grade products to European markets, including through B2B distribution. Comparable to Northern Leaf as a smaller European medical cannabis producer targeting pharmaceutical supply chains.

10Wayland Group / ICC International Cannabis Corp
TypeEmerging player
Description

European-focused medical cannabis operator with EU-GMP certified production assets supplying pharmaceutical distributors across the UK and EU. Comparable to Northern Leaf in targeting the same UK/European pharmaceutical B2B market with EU-GMP certified product.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Northern Leaf

Medical Cannabis Cultivationnorthern-leaf.com

Northern Leaf is a Jersey-based, EU-GMP-certified medical cannabis cultivator that produces pharmaceutical-grade cannabis for export to UK and European pharmaceutical distributors. The company operates on a pre-sold B2B model, exporting approximately 6 tons annually with planned expansion to 9 tons.

What Northern Leaf does

Northern Leaf is a Jersey-based medical cannabis cultivator operating under a bulk EU-GMP licence, producing pharmaceutical-grade cannabis for export to UK and European pharmaceutical supply chains. Founded in the wake of Jersey's 2017 regulatory changes permitting medicinal cannabis cultivation, the company utilizes repurposed greenhouses on the island as its primary production infrastructure and is positioned as a major employer within Jersey's nascent biopharmaceutical sector, which collectively employs approximately 70 people.

Northern Leaf firmographics

Firmographics
Name
Northern Leaf
Legal name
Northern Leaf
Website
https://northern-leaf.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Northern Leaf is a Jersey-based, EU-GMP-certified medical cannabis cultivator that produces pharmaceutical-grade cannabis for export to UK and European pharmaceutical distributors. The company operates on a pre-sold B2B model, exporting approximately 6 tons annually with planned expansion to 9 tons.
Ownership category
akta.pro rank

Northern Leaf industry classification

Industry
Product category
Medical Cannabis Cultivation
NAICS
Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Medicinal Chemicals & Botanical Products (2833), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYCRAOAIAF
Cannabis Wholesale Distribution (Flower, Extracts, Edibles)
Consumer Products & Retail/Wholesale, Distribution & Category Management/Alcohol, Tobacco & Cannabis Wholesale Distribution

Keywords

  • Medical cannabis cultivation
  • Pharmaceutical cannabis production
  • EU-GMP certified cannabis
  • Bulk cannabis supply
  • Medical marijuana manufacturing

Where Northern Leaf is headquartered

Location

Headquarters

HQ city
St. Helier

Offices1 record

Markets served

Northern Leaf business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Others

Revenue model

  1. Medical Cannabis Product Sales: Northern Leaf generates revenue through the production and sale of medical cannabis to pharmaceutical supply chains. The company exports cannabis products to UK and European pharmaceutical markets. All production over the past five months has been sold, and future harvests are pre-sold into target markets, indicating a strong demand-driven revenue model with contracted sales.

Go-to-market motion1 record

Distribution channels2 records

Northern Leaf product offering

Product offering

Core offering

Northern Leaf cultivates and produces pharmaceutical-grade medical cannabis in Jersey under a bulk EU-GMP licence. The company exports approximately 6 tons of medical cannabis in 2025 with plans to increase to 9 tons in 2026, supplying UK and European pharmaceutical companies and distributors. All recent production has been pre-sold into target markets, indicating contracted B2B supply relationships.

Product overview

Northern Leaf operates as a single-product medical cannabis company focused on cultivation and production of pharmaceutical-grade cannabis. The company holds a bulk EU-GMP licence enabling it to supply the UK and European pharmaceutical markets. All production is pre-sold into target markets, with the company exporting approximately six tons annually and planning to increase to nine tons in subsequent years. The core product is the medical cannabis production output itself, which serves the regulated pharmaceutical supply chain.

Differentiator

Problem solved

Functional benefit

Products and services

  • Medical Cannabis Production Cultivation and production of pharmaceutical-grade medical cannabis under a bulk EU-GMP licence for export to UK and European pharmaceutical supply chains. Operating from repurposed greenhouses in Jersey, with production scaled to approximately 6 tons in 2025 and planned 9 tons in 2026.

Companies that use Northern Leaf

Customer profile

Segments1 record

Ideal customer profiles1 record

Northern Leaf technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Northern Leaf partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves5 records

Expansion highlights3 records

Northern Leaf competitors and assessment

Company assessment

Broad incumbents

  • Tilray Brands: Large global cannabis company with significant medical cannabis operations in Europe, including Portugal-based cultivation and EU-GMP certified production. Comparable to Northern Leaf as a competing supplier of EU-GMP certified medical cannabis to European pharmaceutical supply chains, but at vastly greater scale and broader product range.
  • Aurora Cannabis: Major Canadian-listed cannabis producer with EU-GMP facilities in Europe supplying medical cannabis to UK and German markets. Comparable as a competing EU-GMP-certified bulk medical cannabis exporter, though Aurora operates at significantly larger scale with a broader product portfolio.
  • Canopy Growth: Global cannabis producer with medical cannabis operations across Europe, including Spectrum Therapeutics. Comparable to Northern Leaf in targeting the UK and European medical cannabis supply chains with EU-GMP certified product, but with much broader geographic reach and product range.
  • Curaleaf International: Operates one of the largest EU-GMP certified medical cannabis production facilities in Europe (Portugal) and supplies pharmaceutical distributors across the UK and EU. Direct comparable to Northern Leaf in product category (EU-GMP bulk medical cannabis) and customer base, but at much greater scale.

Direct peers

  • OrganiGram Holdings: Canadian cannabis producer that has invested in EU-GMP certified production (Germany) to supply the European medical cannabis market. Comparable to Northern Leaf in business model (EU-GMP certified bulk medical cannabis exporter to European pharma supply chains).
  • Little Green Pharma: Australian medical cannabis producer with EU-GMP certified Danish operations supplying European pharmaceutical markets. Highly comparable to Northern Leaf as a smaller-scale EU-GMP certified medical cannabis exporter focused on European B2B pharmaceutical supply chains.
  • Demecan: German medical cannabis producer holding a domestic cultivation licence and supplying the German and broader European pharmaceutical market. Comparable to Northern Leaf as a regional EU-GMP certified medical cannabis cultivator serving European pharmaceutical supply chains.
  • Bedrocan: Dutch medical cannabis producer with decades of experience supplying pharmaceutical-grade cannabis to European markets under strict regulatory frameworks. Comparable to Northern Leaf in product category (EU-GMP-equivalent pharmaceutical grade medical cannabis) and customer base, though Bedrocan is a long-established incumbent.
  • Stenocare: Danish medical cannabis company supplying pharmaceutical-grade products to European markets, including through B2B distribution. Comparable to Northern Leaf as a smaller European medical cannabis producer targeting pharmaceutical supply chains.

Emerging players

  • Wayland Group / ICC International Cannabis Corp: European-focused medical cannabis operator with EU-GMP certified production assets supplying pharmaceutical distributors across the UK and EU. Comparable to Northern Leaf in targeting the same UK/European pharmaceutical B2B market with EU-GMP certified product.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Northern Leaf compliance and trust

Trust signal

Compliance1 record

Northern Leaf financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Northern Leaf leadership team

Management profile

Number of profiles

Northern Leaf funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Northern Leaf M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Northern Leaf

What does Northern Leaf do?

Northern Leaf cultivates and produces pharmaceutical-grade medical cannabis in Jersey under a bulk EU-GMP licence. The company exports approximately 6 tons of medical cannabis in 2025 with plans to increase to 9 tons in 2026, supplying UK and European pharmaceutical companies and distributors. All recent production has been pre-sold into target markets, indicating contracted B2B supply relationships.

Is Northern Leaf a public or private company?

Northern Leaf is a private company. It is classified as venture growth investor backed and is currently operating.

When was Northern Leaf founded?

Northern Leaf was founded in 2019. It employs 11 to 50 people.

Where is Northern Leaf based?

Northern Leaf is headquartered in St. Helier.

How does Northern Leaf make money?

One revenue line is on record: medical Cannabis Product Sales.

Who are Northern Leaf's main competitors?

Broad incumbents on record are Tilray Brands, Aurora Cannabis, Canopy Growth and Curaleaf International. Direct peers are OrganiGram Holdings, Little Green Pharma, Demecan, Bedrocan and Stenocare. Wayland Group / ICC International Cannabis Corp is listed as an emerging player.

Does Northern Leaf have an API?

No public API is recorded for Northern Leaf.

What industry is Northern Leaf in?

Northern Leaf's product category is Medical Cannabis Cultivation. Its primary akta.pro industry code is CRAOAIAF, Cannabis Wholesale Distribution (Flower, Extracts, Edibles). Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Jersey Evening PostMinister backs call for political “recommitment” to cannabis industryJersey's Economic Development Minister Kirsten Morel has backed calls for political recommitment to the island's medicinal cannabis industry, which achieved its first profit in 2025 with over £12m in sales and employs 70 people. The minister acknowledged that political enthusiasm had waned due to neighbour objections—particularly around Northern Leaf, Jersey's largest cannabis farm—and earlier concerns about profitability, but now sees the sector as a model for economic diversification. Morel stated the industry, which took approximately eight years to become profitable, represents high-value, low-footprint sectors that will be taxed at 20% and contribute revenue to the exchequer.MMJDailyNorthern Leaf grows exports as Jersey regulations and old glasshouses unlock new opportunitiesNorthern Leaf, a Jersey-based medical cannabis producer, has credited the island's commercial licensing regime and access to repurposed greenhouses for enabling its expansion into UK and European pharmaceutical supply chains. The company expects to export approximately six tons of medical cannabis this year and nine tons next year, with all production over the past five months already sold and future harvests pre-sold into target markets. Northern Leaf, operating under new management for 14 months, holds a bulk EU-GMP licence and plans to increase supply to the UK medical-cannabis market in 2026, where current demand is estimated at 20–25 tons.